Conversation 167: PainChek CEO says on track to hit $6 to $7 million in annual recurring revenue.

In my latest CEO Conversation, Philip Daffas of PainChek [ASX:PCK] explains how the value of the share price of the business is lagging behind the value.

“I think that the share price clearly under represents our achievements as we are no longer a speculative company” CEO Philip Daffas said.

In a wide ranging chat he also explains how COVID has resulted in a complete digitisation of the marketing, sales and installation processes of their app.

“A bit like my experience at Cochlear, the more we deliver, the more the share price will evolve” he told me during our Conversation.

Daffas also outlines the latest on progress with both the Phillips Health deal and the TGA and CE mark applications for their child care app.